Radiation therapy for neovascular age-related macular degeneration revisited

British Journal of Ophthalmology

Volumn 93, Issue 3, 2009, Pages 279-280

  Kim, Ivana K ^a   Gragoudas, Evangelos S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; STEROID; STRONTIUM 90; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

BRACHYTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTON RADIATION; RADIATION DOSE; RADIATION INJURY; RADIATION SAFETY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULOPATHY; RETINA NEOVASCULARIZATION; RETINOPATHY; SUBRETINAL NEOVASCULARIZATION; VASCULAR DISEASE; VISUAL ACUITY; VITRECTOMY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; HUMANS; MACULAR DEGENERATION; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 61749103368     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.153296     Document Type: Editorial

References (19)

1. Ávila MP, Farah ME, Santos A, et al. Twelve-month short-term safety and visual acuity results from a multicentre, prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Br J Ophthalmol 2009;93:305-9.
2. Chakravarthy U, Houston RF, Archer DB. Treatment of age-related subfoveal neovascular membranes by teletherapy: a pilot study. Br J Ophthalmol 1993;77:265-73.
3. RAD Study Group. A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study). Ophthalmology 1999;106:2239-47.
4. Hart PM, Chakravarthy U, Mackenzie G, et al. Visual outcomes in the subfoveal radiotherapy study: a randomized controlled trial of teletherapy for age-related macular degeneration. Arch Ophthalmol 2002;120:1029-38.
5. Marcus DM, Sheils W, Johnson MH, et al. External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: one-year results of a prospective, double-masked, randomized clinical trial. Arch Ophthalmol 2001;119:171-80.
6. Marcus DM, Peskin E, Maguire M, et al. The age-related macular degeneration radiotherapy trial (AMDRT): one year results from a pilot study. Am J Ophthalmol 2004;138:818-28.
7. Bergink GJ, Hoyng CB, van der Maazen RW, et al. A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: radiation versus observation. Graefes Arch Clin Exp Ophthalmol 1998;236:321-5.
8. Finger PT, Gelman YP, Berson AM, et al. Palladium-103 plaque radiation therapy for macular degeneration: results of a 7 year study. Br J Ophthalmol 2003;87:1497-503.
9. Flaxel CJ, Friedrichsen EJ, Smith JO, et al. Proton beam irradiation of subfoveal choroidal neovascularisation in age-related macular degeneration. Eye 2000;14:155-64.
10. Zambarakji HJ, Lane AM, Ezra E, et al. Proton beam irradiation for neovascular age-related macular degeneration. Ophthalmology 2006;113:2012-19.
11. Jaakkola A, Heikkonen J, Tommila P, et al. Strontium plaque brachytherapy for exudative age-related macular degeneration: three-year results of a randomized study. Ophthalmology 2005;112:567-73.
12. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
13. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
14. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27:133-40.
15. Samuel MA, QUEST Investigator Study Group. Verteporfin PDT in double or triple combination therapy: the Visudyne(R) QUEST Registry. Invest Ophthalmol Vis Sci 2008;49:ARVO E-abstract 261.
16. Gragoudas ES, Li W, Lane AM, et al. Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology 1999;106:1571-7; discussion 1577-8.
17. Tsao H, Goel V, Wu H, et al. Genetic interaction between NRAS and BRAF mutations and PTEN/ MMAC1 inactivation in melanoma. J Invest Dermatol 2004;122:337-41.
18. Nordal RA, Nagy A, Pintilie M, et al. Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. Clin Cancer Res 2004;10:3342-53.
19. Fung A, Lalwani G, Rosenfeld P, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83.e562.